YH 017
Alternative Names: YH-017Latest Information Update: 24 Apr 2023
At a glance
- Originator Beijing Biocytogen
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 14 Apr 2023 Early research in Autoimmune disorders in China (unspecified route) before April 2023 (Beijing Biocytogen pipeline, April 2023)